Importantly, exhaustion can be reversed, as evidenced by the remarkable clinical success of immune checkpoint inhibitors (ICIs) targeting PD-1 or CTLA-4, which reverse T cell exhaustion and are now established therapies for several cancers [27,28,29,30,31]. This evidence concerns the gene PDCD1 and cancer.